Non-steroidal aldosterone receptor antagonism: a 'fine' treatment for heart failure patients?

Eur J Heart Fail. 2022 Jun;24(6):1006-1008. doi: 10.1002/ejhf.2537. Epub 2022 May 23.

Authors

Rabea Asleh^{1

2}, Alexandros Briasoulis³, Barry A Borlaug²

Affiliations

¹ Heart Institute, Hadassah University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
² Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
³ Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 35560753
DOI: 10.1002/ejhf.2537

No abstract available

Publication types

Editorial
Comment

MeSH terms

Aldosterone*
Heart Failure* / drug therapy
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use
Receptors, Mineralocorticoid
Spironolactone / therapeutic use

Substances

Mineralocorticoid Receptor Antagonists
Receptors, Mineralocorticoid
Spironolactone
Aldosterone